Immutep (ASX:IMM) completed the enrolment target of 40 patients for the EFTISARC-NEO second phase trial in Warsaw, Poland, according to a Wednesday filing with the Australian bourse.
The EFTISARC-NEO trial is evaluating the immunotherapy eftilagimod alpha in combination with radiotherapy Keytruda in the neoadjuvant setting for patients with resectable soft tissue sarcoma, the filing said.
It earlier reported that the combination achieved a greater than three-fold increase in tumor hyalinization/fibrosis at the time of surgical resection among 21 patients available for primary endpoint assessment.
Data updates from the trial are expected in 2025, per the filing.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。